InvestorsHub Logo
Followers 3
Posts 531
Boards Moderated 0
Alias Born 01/13/2013

Re: TechKim post# 160

Thursday, 01/26/2017 10:35:50 AM

Thursday, January 26, 2017 10:35:50 AM

Post# of 551
This is from Jefferies Americas
Thesis Update:
TherapeuticsMD (TXMD, BUY, PT $18) Compounding Pharmacy Tour: TX-001 Market Opportunity Is Under-Appreciated - Investor tour of local compounding pharmacy provided unique insights into '001 market opportunity and reinforced our view that the bioidentical E+P VMS market is at a minimum 5.1M scrips or $714-$893M in sales (assumes 100% conversion of scrips). Bear thesis is '001 is a $50M product at peak; we disagree. TXMD is also leveraging similar strategy that grew Makena from $12M in sales to a $250M+ drug, a positive in our view. TXMD is a top small-cap pick for 2017
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TXMD News